Skip to main content
. 2020 Dec;9(6):2391–2400. doi: 10.21037/tlcr-20-1252

Figure 4.

Figure 4

Kaplan-Meier curves of OS (A,B) and PFS (C,D) from original data and weighted data in the subgroup of patients who had SD/PD as their best response to previous line of therapy. IBP, immunotherapy beyond progression; non-IBP, non-immunotherapy beyond progression; mOS, median overall survival; mPFS, median progression-free survival; HR, hazard ratio; CI, confidence interval.